Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline UpdateN. Lynn Henry, Angela DeMichele, Kelly M. Shanahan et al.|Journal of Clinical Oncology|2022Cited by 127
Effect of Capivasertib in Patients With an <i>AKT1 E17K</i>-Mutated TumorKevin Kalinsky, Keith T. Flaherty, Fangxin Hong et al.|JAMA Oncology|2020Cited by 106
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trialAaron S. Mansfield, Keith T. Flaherty, Zihan Wei et al.|npj Precision Oncology|2022Cited by 42
Phase II Study of Erdafitinib in Patients With Tumors With <i>FGFR</i> Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1Jun Gong, Keith T. Flaherty, Alain C. Mita et al.|JCO Precision Oncology|2024Cited by 16